Antinol vs Dasuquin: Is the Best-Evidenced Joint Supplement Worth Six Times the Price?

Buy Antinol Plus if your dog has diagnosed hip osteoarthritis, you have already given a glucosamine chew six honest measured weeks and got nothing, and roughly $1,300 a year is money you can carry indefinitely — because this is the one product in the aisle whose exact compound beat a placebo on a force plate. Buy Dasuquin with MSM if you have not yet run that cheaper experiment, if the budget has a ceiling, or if you want the label where every milligram is printed and checkable — accepting that a tub bearing this exact name was tested in the same trial and did not move (today's label prints three actives the paper's panel does not — the receipt reaches the name, not the batch). Buy neither if nobody in the house will write down what improvement would justify the money and re-check it in six weeks; without that, both of these are a $207 or $1,300 subscription to your own hopefulness. We earn the same rate on both. Nothing changes for us whichever you pick.

The rare part: these two were in the same trial#

Almost every supplement comparison is an argument between two marketing departments. This one is not, and that is the only reason it is worth your time.

In 2023 a research group at Khon Kaen University, with B. Duncan X. Lascelles as senior author, ran a prospective, block-randomised, double-blinded, placebo-controlled trial in 75 owned pet dogs with hip osteoarthritis. Five arms. One of them received EAB-277 — the marine oil blend inside Antinol Plus. Another received, in the paper's own words, "Glucosamine HCL and chondroitin sulfate (DASUQUIN®) with MSM Soft Chews, Nutramax Laboratories Consumer Care, Inc.; 30 mg of glucosamine HCL based/kg body weight q24hr PO for 6 weeks."^[1] The paper even prints the chew's panel: glucosamine HCl 900 mg, chondroitin 350 mg, MSM 800 mg, ASU 90 mg. That is the large-dog Dasuquin, by name, in a blinded trial. One honesty note before you carry that verdict to today's shelf: the panel the paper prints has four actives, and the tub Nutramax sells under the same name today prints seven — Boswellia, green tea extract and a 90 mg omega-3 line are on the current label and not in the paper's panel. Whether the trial tub contained them unprinted or the formula moved after the trial, the paper cannot tell you. "A tub sold under this name did not separate from placebo" is exactly as far as the receipt reaches — our Dasuquin line map walks the whole family, form by form.

The outcome was peak vertical force on a force plate — how hard the sore leg actually pushes on the ground — not an owner's opinion. At week four:

The three at the top were all significantly greater than both placebo and the glucosamine arm.^[1] By week six the Dasuquin arm had drifted up to +1.08 and, in the authors' phrasing, "lay between the placebo group and the other treatment groups."

So when Antinol's Amazon listing claims it "outperformed leading joint supplements" in head-to-head clinical studies, that sentence is true, it is checkable, and the leading joint supplement it outperformed is the other product on this page. We have not seen another supplement in this category able to say that.

Now the part the listing does not say, and the reason this article is not simply "buy the expensive one."

dogorthopedic.com

The receipts, with a date on every cell#

Every figure below was verified on 16 August 2026 — prices, sellers and listing copy through the Amazon Creators API, panels and dosing off each maker's own current pages, trial figures from the full texts on Europe PMC. "Not published" is an answer, not a gap.

Two rows decide this page, and neither is the price. One is the row where the same company gives the same dog two different maintenance doses. The other is the row where a brand claiming four double-blind trials publishes a reference list containing none of them.

Axis one: the label stops scaling before the dog does#

This is the thesis, and it is the reason a product with genuinely good evidence can still be the wrong purchase.

Antinol Plus is, as far as we can tell, the only joint supplement on the shelf where the item in the tub and the item in the trial are demonstrably the same compound. The PRODUCT FACTS panel names it — "Antinol®+ Proprietary Blend 50 mg — EAB-277® [Green-lipped mussel (Perna canaliculus) oil, Krill (Euphausia superba) oil]" — and adds that "EAB-277® is protected by US patent 11654163."^[5] That is the compound code in both papers. Nobody else in this aisle can offer you that.

Then the dosing instruction throws most of it away.

The trials dosed by weight. The label does not. Both trials gave one capsule per 10 kg of dog — 5 mg/kg once daily in 2023, and the same capsule count twice daily in 2024 for 10 mg/kg.^[1][2] The dose scaled with the dog, all the way up. The consumer label has exactly one step in it, at 45 lb, and nothing above.

Read the bottom two rows against the rest. A 45 lb dog on four a day lands close to the 2024 trial. A 70 lb dog sits between the two trials. A 120 lb dog on four soft gels a day gets less than the lower of the two trial doses, and on two a day gets roughly a third of it. Nothing here is hidden — it is simply what a flat dose does once dogs get big — but no competitor page states it, and it changes what a null result means in your kitchen.

And there are two labels. The US Amazon listing, read this morning, says: "Initial 4 weeks: Up to 44 pounds: 2 soft gels daily; 45+ pounds: 4 soft gels daily. Maintenance (starting week five): Up to 44 pounds: 1- 2 soft gels daily; 45+ pounds: 2-4 soft gels daily."^[3] The company's own New Zealand page for the same product says: "Over 22kg: Initial loading of 4 capsules daily for two weeks, and then 2 daily ongoing."^[7]

Three disagreements in two sentences: the loading phase is four weeks or two; maintenance is two a day or somewhere in a "2-4" range with no rule for choosing; and the weight threshold is 45 lb or 22 kg. For a 70 lb dog the honest reading of that range is a $650 difference per year for the same product from the same company on the same day. Dasuquin's equivalent trap is duller and cheaper to avoid — two formulas split at 60 lb, and every milligram on this page is the large-dog one. The band-by-band figures for every product we cover are in our dosing-by-weight reference.

Axis two: the money, and the count that quietly costs you $187 a year#

Prices below are the one-time Amazon prices verified 16 August 2026. The arithmetic is shown so you can redo it when they move, which they will.

Antinol Plus is sold in five counts, and the price per soft gel does not follow the count.

All five figures verified through the Creators API this morning.^[15] Four are sold by Pet HealthWorks itself; the 120-count is held by a third-party seller. At four soft gels a day, the ladder runs from $1,205 a year at the 120-count to $1,392 at the 90 — a $187 spread on the identical soft gel. Staying with the maker's own listings, choosing the 90 over the 180 still costs about $91 a year for nothing. That is the sort of thing that happens when a shopper assumes the middle size splits the difference. It does not. And note the right-hand column: for a 45 lb-plus dog, the 60 and 90 counts do not survive the four-week loading phase the listing prescribes.

Antinol Plus, 70 lb dog, 180-count. $160.32 ÷ 180 = $0.8907 a soft gel. Four a day is $3.56 a day, or $1,300 a year. Two a day is $1.78, or $650 a year.

Dasuquin with MSM Large, 70 lb dog. $84.99 ÷ 150 = $0.5666 a chew. One a day at maintenance is $207 a year; year one including the loading phase is about $231.

So the headline in the title checks out: 6.3 times, at the loading dose, against the cheaper product's steady state. At the lower of Antinol's two published maintenance doses it is 3.1 times — but that dose is the one that puts a 70 lb dog below both trials.

And here is the number that makes the whole thing uncomfortable. If you wanted to buy the dose that produced the 2024 result — 10 mg/kg — you would need 6.4 soft gels a day for a 70 lb dog, about $2,064 a year, or 10.9 a day for a 120 lb dog, about $3,539 a year. Nobody sells that as a schedule and we are not recommending it. We are pointing out that the evidence everybody cites for this product and the instruction on the bottle are not the same thing, and the difference is roughly the price of the product all over again.

dogorthopedic.com

Axis three: what each company lets you check#

This is where the two products swap places, and it is the most interesting thing on the page.

Dasuquin publishes a number for every active and has nothing else to hide behind. Per large-dog chew: 900 mg glucosamine hydrochloride, 350 mg sodium chondroitin sulfate, 800 mg MSM, 90 mg avocado/soybean unsaponifiables, 40 mg Boswellia serrata extract, 32 mg decaffeinated green tea extract. Six ingredients, six figures. Anyone can audit that dose against any study they like — which is precisely how the trial that embarrassed it became readable in the first place.

Antinol names its compound and then stops. The panel gives one number, 50 mg, for a proprietary blend.^[5] The split between mussel oil and krill oil — 30 mg and 20 mg — is published by the brand in New Zealand and Australia and is not on the US panel. In fairness, a blend total matters far less here than it usually would, because the trials dosed that same 50 mg capsule; you are not being asked to guess whether the ratio matches the study. But there is a stranger gap around it. The string "EAB-277" appears in zero lines of text on any US-facing web property we can reach. It exists only inside the pack-shot artwork. Search the listing text and you will not find the ingredient the entire scientific case rests on.

There is a reason for that, and it is the next finding.

The four studies, and the reference list that does not contain them#

Every Antinol Plus listing carries this, verbatim: "Antinol Plus is backed by four double-blind, placebo-controlled clinical studies and 40 years of research."^[3] The pack artwork repeats it as "Efficacy: High - 4 clinical studies & 40 years of research" alongside "Head to Head: Outperformed competitors in clinical trials." Four studies are named nowhere.

The brand's own surfaces do not agree on the count either. Verified this morning:

That last row is the one worth dwelling on, because we counted it by hand this morning. The only dedicated reference list the brand publishes anywhere lists thirteen citations — and two of them are the same paper. McPhee and colleagues' 2007 anti-cyclooxygenase study in Comparative Biochemistry and Physiology B appears twice, once as "green-lipped mussel" and once as "Green shell mussel," same authors, same volume, same issue, same pages 346–356.^[6] So twelve distinct papers.

Of those twelve, several are in rats, one is in human monocytes, one is a cell-cycle assay, one is a survey of over-the-counter arthritis remedies in people, and the canine ones are on PCSO-524 — the older mussel-oil-only product. Not one of the twelve is a study of EAB-277. Neither Kampa trial — the two papers that are the entire reason this product deserves shelf space — appears on the brand's own reference page.

Say it plainly, because it is genuinely odd: the company is under-citing itself. It advertises four unnamed double-blind trials, publishes a list of thirteen papers that contains none of them, and leaves the two real ones — which are open-access, indexed, and good — for a reader to find on their own. We found them. They are in the next section. But a vet asked to justify $1,300 a year should not have to.

Axis four: how good the evidence actually is, stated against our own interest#

Antinol is the more expensive product and it earns us more per sale. So here is the case against it, in full.

The 2024 trial is the better one and it is genuinely strong. Same design, 101 pet dogs with hip osteoarthritis, four arms: EAB-277 at 10 mg/kg, Biota orientalis (4CYTE Epiitalis Forte), meloxicam, and a sunflower-oil placebo. Using a pre-specified responder threshold — a peak vertical force gain of more than 2% of body weight — the week-six results were:^[2]

Sixty-nine percent against eight percent is an individual-dog number almost nothing in this category can produce, and it comes from a force plate rather than an owner's impression — which matters enormously, because owners in blinded trials report improvement on a sugar pill 39.7% of the time while the ground reaction forces do not move at all.^[14]

Now the five things that should stop you treating it as settled.

1. Both trials were paid for by the company that owns the ingredient. Both funding statements read: "This work was funded by Pharmalink International Ltd., Central, Hong Kong."^[1][2] Both papers add that the funder was not involved in design, analysis or the decision to publish, which is the right declaration to make. Pharmalink also manufactured the placebo capsules. Sponsor funding does not make a result wrong; it does mean the result wants replicating by someone with no stake, and that has not happened.
2. One research group, both times. Identical author list, same university, same force plate. Independent replication of EAB-277 has not been published.
3. The 2023 trial's subjective scores did not move for anyone. The orthopedic assessment score "did not show any significant change in any group" — including carprofen.^[1] A force plate detected something a clinician's structured assessment did not. In 2024 the assessment scores did separate. Both facts belong on the record, and the first is a fair warning about how visible this effect may be at home.
4. "Matched an NSAID" is a hedge, not a finding. Look at the confidence intervals above: EAB-277's runs 48–86% and meloxicam's runs 58–93%. They overlap heavily. Neither trial was designed as a formal non-inferiority test, so what was shown is that both beat placebo, not that they are equivalent. Nobody should stop a prescribed pain medicine on the strength of that table.
5. A disclosure difference between the two papers. The 2023 paper discloses that the senior author "has been a paid consultant for VetzPetz Asia Company," noting no payment in connection with that study. The 2024 paper's conflict-of-interest statement declares no commercial or financial relationships.^[1][2] We report that as printed and draw no conclusion from it; readers can weigh it themselves. VetzPetz, incidentally, is the brand name on the domain that Antinol's own US web address now redirects to.

And Dasuquin's fair defences, which we owe it: fifteen dogs per arm cannot exclude a modest effect, that trial was powered to detect the mussel extract's benefit rather than to rule out a smaller one, and it ran maintenance dosing — about one large-dog chew — through the exact six weeks the label tells you to give two. Nobody has run the trial at Dasuquin's loading dose. A second group reached the same null by a different route, with 30 dogs on glucosamine/chondroitin and 30 on placebo wearing activity monitors for 97 days and no difference in activity counts.^[17] The fuller picture, including how we walked back our own Dasuquin score, is in green-lipped mussel vs glucosamine.

So the honest summary of this axis is a swap. The product with the better evidence has the worse paperwork: a compound named only in artwork, a blend ratio withheld from Americans, a study count that contradicts itself across three surfaces, and a reference list missing its own best papers. The product with the better paperwork has the worse result: every milligram printed, and a blinded force plate that could not tell it from sunflower oil.

Those ranks reflect published evidence quality for the compound in the tub. They are not a claim that either product will help your dog, and they deliberately ignore price — which is why the verdict at the top of this page does not simply follow them.

Axis five: the channel, and the guarantee that stops at the border#

We publish this even when it costs us the commission. This time it does not cost us anything, which is its own finding.

Neither product has a US manufacturer store you can buy from. Antinol's US direct domain, antinolplus.com, 301-redirects to vetzpetz.org, which 302-redirects to a password page titled "Opening Soon" — checked again this morning, and the destination domain has changed since our last pass without the store ever opening.^[11] Pet HealthWorks' entire US web presence is still one page: its sitemap contains exactly one URL, https://www.pethealthworks.com, last modified 24 July 2026.^[10] Nutramax gets to the same place from the opposite direction: it runs a real direct store at store.cosequin.com, and that store's 17 products are all Cosequin lines with no Dasuquin at all.^[12] Dasuquin is kept in the veterinary and retail channel, where clinics price it themselves and frequently above Amazon.

There is no channel saving to report on either product, so the practical advice is smaller and duller: buy the right count, and on Antinol that means the 180 rather than the 90.

The guarantee, though, is a real asymmetry, and it runs against the American buyer. Antinol offers a 60-day money-back guarantee in New Zealand — "If you don't notice enhancements in your pet's mobility, skin, or coat health, email us and we'll refund your purchase – no questions asked" — and an equivalent 60-day trial on starter packs in Australia.^[13] A US buyer gets no published manufacturer guarantee of any kind; the only remedy we can actually point at is Amazon's own returns process. Nutramax is no better and arguably worse: report within 10 business days, and after that returns are accepted only if the tub is unopened.^[16]

So on both products, the American owner is asked to commit four to six weeks before judging, and has no way to get the money back if the answer is no. Plan for that: the money is spent when you click.

dogorthopedic.com

Who should buy neither#

In order, cheapest first. This is most readers.

1. The owner unwilling to run a measured six-week trial either way. This is the disqualifier that matters, and it applies identically to a $207 product and a $1,300 one. Both labels ask for four to six weeks at a doubled dose before judging. If nobody in the house will write down a starting point today and re-check it in six weeks, you will be paying indefinitely for something you cannot evaluate — and with a measured 39.7% caregiver placebo rate, you will probably feel sure it worked.^[14] The measurement is free. Start there, with our printable supplement trial scorecard and the method in is my dog's limp getting better.
2. The overweight dog's owner, who should ask for a body condition score first. Weight is the largest modifiable factor in canine arthritis and has less controversy behind it than anything on this page. It also costs nothing to ask about at the next appointment.
3. Anyone whose dog is sore right now. In both of these trials the NSAID arm worked — it was the benchmark, not the control that failed. If your dog is painful today, the supplement question is not the urgent one, and how to tell if your dog is in pain is the more useful page.
4. Anyone who has not yet given the cheap option a fair run. Dasuquin's trial result is bad, but a sixth of the price buys you a real six-week experiment, and the $1,100 you did not spend is still there afterwards. Running the expensive product first tells you nothing the cheap one had not yet ruled out.
5. Anyone buying green-lipped mussel because a chew's label says it contains some. The mussel that worked in these trials is a concentrated marine lipid extract at 50 mg a capsule, not the dried whole-mussel powder in the shelf chews. Those are different substances and the powder has never been through a blinded force-plate trial. That comparison is green-lipped mussel vs glucosamine; if what you actually want is Dasuquin's ingredients for less money, the case is in Dasuquin vs Cosequin.

What we could not verify#

• The four double-blind studies, by name. Four are claimed on every US listing and in the pack artwork. No Antinol or Pet HealthWorks property names them, and the brand's only reference page contains none of them. We found two ourselves; the other two, if they exist, are not published anywhere we can reach.
• A "15+ studies" claim. Recorded in our own earlier research, not reproducible on any live surface today. Withdrawn rather than repeated.
• The mussel-to-krill split for a US buyer. 30 mg and 20 mg are published in New Zealand and Australia; the US panel gives only the 50 mg total.
• Calories per unit, for either product. Neither Pet HealthWorks nor Nutramax publishes it, and a 45 lb-plus dog eats four Antinol soft gels a day.
• Any US manufacturer guarantee for Antinol Plus. None published; the NZ and AU 60-day terms are explicitly for those markets.
• Country of manufacture for Antinol Plus. Not on the US panel or listing.
• Whether the 120-count's third-party seller is authorised by Pet HealthWorks. The listing gives no answer either way, and no authorised-seller policy is published for us to check it against.
• Subscribe-and-save pricing on either product. The Creators API returned no subscription price for these ASINs this morning, so we are not printing one.

What to do this week#

Weigh the dog, then do one piece of arithmetic before you spend anything. Multiply his weight in kilograms by five. Divide by fifty. That is how many soft gels a day the 2023 trial would have given him. Compare it against the four the bottle says. If your dog is over about 80 lb, those two numbers are not close, and that gap is the single most useful thing you now know that no product page will tell you.

Then write one line on a piece of paper: the specific thing you would need to see by the end of September to keep paying for this. The first three minutes after he gets up. The jump into the car. Whether he takes the stairs one at a time. Date it. Put it where you will find it again.

That sentence is worth more than the $1,100 a year between these two products, because it is the only thing on this page that can tell you whether either of them earned the money. Everything else — the funded trials, the reference list missing its own best papers, the label that stops scaling at 45 lb — is us doing the reading so you do not have to.

The part only you can do is noticing, honestly, whether he got up any easier. He will not tell you. He will just swallow the soft gel, because it is small and it tastes of fish, and go back to lying down.